Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
Resmed announced that Chief Financial Officer Brett Sandercock will retire effective May 4, 2026, after 27 years with the company, and named Aaron Bloomer as his successor. Bloomer joins from Exact Sciences, bringing over 17 years of experience from roles at Exact Sciences, Baxter International, and 3M, while Sandercock will serve as an advisor through the end of 2027.
Key figures
- Guidance
- FY2026 gross margin 62-63%, SG&A 19-20%, R&D 6-7%, effective tax rate 21-23%
- Sandercock tenure years
- 27
- Bloomer experience years
- 17
- Sandercock cfo tenure years
- 20
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.